| 04/26 | OpSens Announces Health Canada Approval For Its New TAVR Guidewire | MT |
| 04/26 | Opsens announces health canada approval for its new tavr guidewire | AQ |
| 04/26 | Opsens Inc. Announces Health Canada Approval for Its New TAVR Guidewire | CI |
| 04/13 | TRANSCRIPT : Opsens Inc., Q2 2022 Earnings Call, Apr 13, 2022 | CI |
| 04/13 | OPSENS : CEO Certification | PU |
| 04/13 | OPSENS : CFO Certification | PU |
| 04/13 | Opsens Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Februa.. | CI |
| 04/13 | OpSens Swings to Loss in Fiscal Q2 as Consolidated Sales Drop | MT |
| 04/13 | OPSENS BRIEF : Net loss was $2.4 million in Q2 2022 compared with a net income of $41,000 .. | MT |
| 04/13 | OPSENS BRIEF : Consolidated sales were $8.1 million in Q2 2022, compared with $8.8 million.. | MT |
| 04/13 | Opsens announces second quarter fiscal 2022 financial results | AQ |
| 04/06 | Opsens to host second quarter fiscal year 2022 financial results conference call on wed.. | AQ |
| 03/14 | OpSens to Participate in the 32nd Annual Oppenheimer Healthcare Conference March 15th t.. | AQ |
| 02/25 | OpSens Reports on Voting Results from its Annual Shareholders Meeting | AQ |
| 02/09 | Opsens appoints brad davis as new chief commercial officer | AQ |
| 02/09 | OpSens Inc Appoints Brad Davis as Chief Commercial Officer | CI |
| 02/01 | Toronto Stocks Rise; Couche-Tard Rises After Increased Buyback | DJ |
| 02/01 | OpSens Details Abiomed 4-Year Supply Agreement Extension to 2028 | MT |
| 02/01 | Opsens announces abiomed 4-year supply agreement extension to 2028 | AQ |
| 02/01 | OpSens Inc. Announces Abiomed 4-Year Supply Agreement Extension to 2028 | CI |
| 01/28 | OPSENS : Corrected and Refiled Financial Statements 2021 | PU |
| 01/28 | OPSENS : Form 52-109f1r | PU |
| 01/24 | Opsens named to 2022 otcqx best 50 | AQ |
| 01/13 | OPSENS : 52-109 F2 CEO Certification | PU |
| 01/13 | OPSENS : 52-109 F2 CFO Certification | PU |
| 01/13 | TRANSCRIPT : Opsens Inc., Q1 2022 Earnings Call, Jan 13, 2022 | CI |
| 01/13 | Opsens Inc. Reports Earnings Results for the First Quarter Ended November 30, 2021 | CI |
| 01/13 | OpSens Reports Q1 Loss of $0.02 Per Diluted Share, as Q1 Revenue Misses Forecast | MT |
| 01/13 | OPSENS BRIEF : Q1 Revs $8.096 Million Vs Forecast 8.53 Million and Last Year 8.34 Million | MT |
| 01/13 | OPSENS BRIEF : Q1 EPS Basic and Diluted ($0.02) Vs Forecast EPS Normalized ($0.01) As Per .. | MT |
| 01/13 | OpSens Announces FIRST Quarter fiscal 2022 Financial Results | AQ |
| 01/06 | Opsens to host first quarter fiscal year 2022 financial results conference call on thur.. | AQ |
| 2021 | OPSENS : Annual Information Form | PU |
| 2021 | OPSENS : Management information circular - English | PU |
| 2021 | OPSENS : Notice of meeting - French | PU |
| 2021 | OPSENS : Proxy | PU |
| 2021 | OPSENS : Management Information Circular | PU |
| 2021 | OPSENS : Annual Report 2021 | PU |
| 2021 | OpSens Announcing Submission To U.S. FDA For New Guidewire For TAVR Procedure | MT |
| 2021 | OPSENS BRIEF : Announcing Submission To U.S. FDA For New Guidewire For TAVR Procedure | MT |
| 2021 | Opsens announces 510(k) submission to u.s. fda for new guidewire for the tavr procedure | AQ |
| 2021 | Opsens Inc. Announces 510(K) Submission to U.S. FDA for New Guidewire for the Tavr Proc.. | CI |
| 2021 | OPSENS TO PRESENT AT THE LYTHAM PART : Presentation at 11 Am (ET), Monday December 13, 202.. | AQ |
| 2021 | OPSENS : Certification CEO | PU |
| 2021 | OPSENS : Certification CFO | PU |
| 2021 | Opsens Upgraded to Strong Buy at Raymond James | MT |
| 2021 | OpSens Reports Q4 $1.2 Million Net Loss; Successfully Completes 20-Patient in Human Cli.. | MT |
| 2021 | OPSENS BRIEF : Adds Net Loss was $1.2 Million during Q4 2021 Vs Net Income of $0.6 Million.. | MT |
| 2021 | OPSENS BRIEF : Says Total Revenue was $8.1 Million in Q4 2021 Compared With $7.6 million i.. | MT |
| 2021 | OpSens Announces Fourth Quarter And Fiscal Year 2021 Financial Results | AQ |
| 2021 | Opsens Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended August .. | CI |
| 2021 | OPSENS BRIEF : Says Successfully Completed 20-Patient in Human Clinical Study for TAVR Pro.. | MT |
| 2021 | OpSens Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedure | AQ |
| 2021 | Opsens Inc. Successfully Completes 20-Patient in Human Clinical Study for TAVR Procedur.. | CI |
| 2021 | OpSens to Host Fourth Quarter Fiscal Year 2021 Financial Results Conference Call and Ye.. | AQ |
| 2021 | OpSens will Participate at Stifel 2021 Virtual Healthcare Conference and Canaccord Genu.. | AQ |
| 2021 | OPSENS' SAVVYWIRE™ Featured at the Transcatheter Cardiovascular Therapeutics 2021.. | AQ |
| 2021 | OPSENS : Says "Successfully Treats" First Patients in Human Clinical Study for TAVR Proced.. | MT |
| 2021 | OPSENS : Successfully Treats First Patients in Human Clinical Study for TAVR Procedure | AQ |
| 2021 | OpSens Successfully Treats First Patients in Human Clinical Study for TAVR Procedure | CI |
| 2021 | OPSENS : to Present at the Lytham Partners Fall 2021 Investor Conference | AQ |
| 2021 | OPSENS : Shares Rise 4% on Health Canada Approval, Raymond James Says Edwards Lifesciences.. | MT |
| 2021 | OPSENS : Receives Health Canada Approval to Initiate First In-Man Clinical Study For Its S.. | MT |
| 2021 | OPSENS : Receives Approval from Health Canada to Initiate First In-Man Clinical Study for .. | AQ |
| 2021 | OPSENS Receives Approval from Health Canada to Initiate First In-Man Clinical Study for.. | CI |
| 2021 | OPSENS : Appoints Lori Chmura to its Board of Directors | AQ |
| 2021 | Opsens Inc. Appoints Lori Chmura to Board of Directors | CI |
| 2021 | TRANSCRIPT : Opsens Inc., Q3 2021 Earnings Call, Jul 13, 2021 | CI |
| 2021 | Opsens Inc. Reports Earnings Results for the Third Quarter Ended May 31, 2021 | CI |
| 2021 | OPSENS : Reports Q3 Loss Per Share of $0.01, Below Forecast | MT |
| 2021 | OPSENS BRIEF : Q3 Basic and Diluted Loss Per Share $0.01 Vs Forecast $0.00 As Per Capital .. | MT |
| 2021 | OPSENS : Announces Third Quarter Fiscal 2021 Record Financial Results | AQ |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Investors Gear -2- | DJ |
| 2021 | OPSENS : to Host Third Quarter Fiscal Year 2021 Financial Results Conference Call on Tuesd.. | AQ |
| 2021 | OPSENS : Gets Funding Support to Jointly Develop Optical-Based Fuel Monitoring System For .. | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
